Moderna

Reduce Your Pets' Carbon Pawprint With Eco-Friendly Products, Courtesy of American Pet Products Association Members

Retrieved on: 
Friday, April 7, 2023
Karma, News, American Pet Products Association, Food, Solid Gold (pet food), Waste, Jax, Dog toy, Comfort, Parent, Pet, Waste management, Fishery, Litter, APPA, Cat, Moderna, Water, Plastic Bank, The Non-GMO Project, Bed, Marine Stewardship Council, Environment, Sustainable Forestry Initiative, Pet industry, Poultry farming

STAMFORD, Conn., April 7, 2023 /PRNewswire/ -- This Earth Month, the American Pet Products Association (APPA) is sharing the latest eco-friendly products to help pets and pet owners prioritize sustainability in their everyday lives.

Key Points: 
  • STAMFORD, Conn., April 7, 2023 /PRNewswire/ -- This Earth Month, the American Pet Products Association (APPA) is sharing the latest eco-friendly products to help pets and pet owners prioritize sustainability in their everyday lives.
  • "Earth Month is the perfect time for pet owners to evaluate their current choice of pet products and explore some of the latest eco-friendly alternatives on the market."
  • Food and Treats – Keep your pet and the planet healthy with food and treats designed to create a positive impact on the environment.
  • Treats like Portland Pet Food Company's Bacon Brew Biscuits are made with upcycled spent grains repurposed from local Portland breweries.

Gandeeva and Moderna Enter into Cryo-EM Research Collaboration to Explore Protein Surface Structure at Atomic Resolution

Retrieved on: 
Thursday, March 30, 2023
Other Health, Research, General Health, Medical Devices, Technology, Artificial Intelligence, Health Technology, Science, Biotechnology, Other Technology, Other Science, Health, MRNA, Therapy, Greater, Machine learning, Medicine, Cancer, Drug discovery, Moderna, Pharmaceutical industry, Vaccine

“Through our internal pipeline programs and collaborations, we are aggressively pursuing the development of first-in-class modalities in targeting difficult-to-drug protein-protein interactions.”

Key Points: 
  • “Through our internal pipeline programs and collaborations, we are aggressively pursuing the development of first-in-class modalities in targeting difficult-to-drug protein-protein interactions.”
    Under the research agreement, Gandeeva and Moderna will study and validate the application of Gandeeva’s proprietary cryo-EM platform approach for an undisclosed Moderna target.
  • Gandeeva will receive research payments from Moderna.
  • Gandeeva Therapeutics is a precision medicine company integrating the power of cryogenic electron microscopy (cryo-EM) and machine learning to develop differentiated therapeutics by targeting and modulating key protein-protein interactions.
  • Gandeeva has a robust preclinical oncology pipeline targeting difficult-to-treat cancers with novel protein interaction modulators such as interfacial glues (iGlues™) and allosteric inhibitors.

CytomX Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update

Retrieved on: 
Monday, March 27, 2023
Amgen, Neoplasm, Lead, Head, Science, Patient, Investment, EGFR, HNSCC, Research, PST, ADC, Safety, Bristol Myers Squibb, AE, CD3, Therapeutic index, Immunotherapy, Messenger, AbbVie, Annual report, SAN, Anemia, CD71, Webcast, Therapy, ORR, Epithelial cell adhesion molecule, Regeneron Pharmaceuticals, Bank statement, Clinical trial, EST, Trial of the century, IND Queens Boulevard Line, Interferon, BMS, Tumor microenvironment, TCB, Pharmaceutical industry, Cryptocurrency, Moderna, IND, Astellas Pharma

“2022 was an important year of transition for CytomX as we proactively restructured our organization to maximize long-term success and value creation.

Key Points: 
  • “2022 was an important year of transition for CytomX as we proactively restructured our organization to maximize long-term success and value creation.
  • CX-904 is being evaluated by CytomX in an ongoing Phase 1 study in patients with advanced solid tumors.
  • The financial results contained in this press release reflect the restated financial statements in CytomX’s most recent SEC filings.
  • ET (2 p.m. PT) to discuss the financial results and provide a business update.

Moderna and Generation Bio Announce Strategic Collaboration to Develop Non-Viral Genetic Medicines

Retrieved on: 
Thursday, March 23, 2023
Vaccine, Tissue, DNA, MRNA, Therapy, Senior, Liver disease, Development, Biotechnology, Generation, RNA, Messenger, Moderna, Patient, Liver, Research, Haemophilia

CAMBRIDGE, Mass., March 23, 2023 (GLOBE NEWSWIRE) -- Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today announced that the two companies have entered into a strategic collaboration to combine Moderna’s biological and technical expertise with core technologies of Generation Bio’s non-viral genetic medicine platform. The collaboration aims to expand the application of each company’s platform by developing novel nucleic acid therapeutics, including those capable of reaching immune cells, to accelerate their respective pipelines of non-viral genetic medicines.

Key Points: 
  • The collaboration aims to expand the application of each company’s platform by developing novel nucleic acid therapeutics, including those capable of reaching immune cells, to accelerate their respective pipelines of non-viral genetic medicines.
  • “Moderna continues to invest in innovative technology to enable us to develop a breadth of transformative medicines for patients,” said Rose Loughlin, Ph.D., Moderna's Senior Vice President for Research and Early Development.
  • “Through this collaboration, which builds on Generation Bio’s non-viral genetic medicines platform, we have the potential to target immune cells with diverse nucleic acid cargos and the liver for gene replacement.
  • We are thrilled to collaborate with Moderna to extend genetic medicines to new tissues and cell types through the joint development of novel targeting for our stealth ctLNPs to reach immune cells.”

BenevolentAI Strengthens its Board of Directors with the Appointment of Digital Innovation Expert Marcello Damiani

Retrieved on: 
Wednesday, March 22, 2023
Enterprise architecture, University of Toulouse, University, Intelligence, MBA, Architecture, Messenger, Bachelor of Science, Science, BAI, Master of Science, Euronext Amsterdam, Information system, Knowledge, CIO, Digital, AI, Marcello, SR, Computer science, Moderna, Operational excellence, Management, EU

596/2014 on market abuse (Market Abuse Regulation)

Key Points: 
  • 596/2014 on market abuse (Market Abuse Regulation)
    BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leading, clinical-stage AI-enabled drug discovery and development company, today announces the appointment of Marcello Damiani to its Board of Directors.
  • His official appointment will be confirmed by the Company’s Annual General Meeting of Shareholders, which will be held on 4 May 2023.
  • Dr. François Nader, Chairman of BenevolentAI, said: “We are pleased to welcome Marcello to our Board as a Non-Executive Director.
  • He also serves on the Board of Cellarity, a biotech company based in Cambridge, MA.

Catalent, Inc. Reports Second Quarter Fiscal 2023 Results

Retrieved on: 
Tuesday, February 7, 2023
Biotechnology, Manufacturing, Other Manufacturing, Health, Pharmaceutical, Vaccine, Sarepta, Messenger, Investment, NYSE, RSV, GAAP, CTLT, Partnership, Ratio, COVID-19, Pharmaceutical industry, Bank, Catalent, Moderna

Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced financial results for the second quarter of fiscal 2023, which ended December 31, 2022.

Key Points: 
  • Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced financial results for the second quarter of fiscal 2023, which ended December 31, 2022.
  • Net revenue of $1.15 billion decreased 6% reported, or 2% in constant currency, from the $1.22 billion reported for the second quarter a year ago.
  • EBITDA from operations(1) was $264 million, an increase of $19 million from $245 million in the second quarter a year ago.
  • Second quarter fiscal 2023 Adjusted EBITDA(1) was $283 million, or 25% of net revenue, compared to $310 million, or 25% of net revenue, in the second quarter a year ago.

Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials

Retrieved on: 
Friday, February 3, 2023
Biotechnology, Technology, Health, Pharmaceutical, Oncology, Health Technology, Medical Devices, Research, Genetics, Science, Clinical Trials, MSD, Moderna, Vaccine, PSNL, Messenger, Therapy, Cancer, Patient, RNA, Partnership, Genomics, MRNA, Pharmaceutical industry, Merck, Chief Justice of Hungary

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, and Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the companies have signed a new agreement to continue using the Personalis NeXT Platform®as part of upcoming clinical studies evaluating mRNA-4157/V940, an investigational personalized cancer vaccine, jointly developed by Moderna and Merck, known as MSD outside of the United States and Canada.

Key Points: 
  • Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, and Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the companies have signed a new agreement to continue using the Personalis NeXT Platform®as part of upcoming clinical studies evaluating mRNA-4157/V940, an investigational personalized cancer vaccine, jointly developed by Moderna and Merck, known as MSD outside of the United States and Canada.
  • The platform, which was also utilized in the vaccine candidate’s Phase 2b clinical study, will be used to sequence genomic information from a patient’s tumor sample to identify the unique genetic mutations that are most likely to generate a tailored antitumor response.
  • “For years, we have been at the forefront of working with pharmaceutical partners, including Moderna, to apply our NeXT Platform to the sequencing of personalized cancer vaccines,” said Chris Hall, President of Personalis.
  • “We are thrilled to enter a new agreement with Moderna and support the next stage of clinical development for this program.”
    “We are looking forward to continuing our partnership with Personalis on our personalized cancer vaccine program, with the goal of helping to bring truly individualized cancer treatment to patients,” said Melanie Ivarsson, Moderna’s Chief Development Officer.

Myosana Therapeutics Raises $5 Million in Seed Funding

Retrieved on: 
Wednesday, January 25, 2023
Research, Genetics, Cardiology, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Medical director, PPMD, Muscular Dystrophy Association, Rare Diseases Clinical Research Network, ARCH Venture Partners, Pfizer, Drug development, Patient, CSO, Muscular dystrophy, Therapy, Duchenne, Rare, Duchenne muscular dystrophy, Lumley, Pharmaceutical industry, Moderna

Myosana Therapeutics, Inc. , pioneer of a muscle-specific non-viral gene therapy platform for neuromuscular and cardiac diseases, today announced the completion of a seed funding round totaling over $5 million led by investor John Ballantyne, Ph.D.

Key Points: 
  • Myosana Therapeutics, Inc. , pioneer of a muscle-specific non-viral gene therapy platform for neuromuscular and cardiac diseases, today announced the completion of a seed funding round totaling over $5 million led by investor John Ballantyne, Ph.D.
  • The capital will go toward developing Myosana’s platform with the goal of identifying the first development candidate for Duchenne muscular dystrophy by 2025.
  • Completion of this major funding round comes just as Myosana has appointed its new CEO, Dr. Matthew Lumley.
  • In his role on Myosana’s Board of Directors, Lumley has been intimately involved in raising seed funding and advancing the platform.

Modular Content Powers Omnichannel Engagement at Speed and Scale

Retrieved on: 
Thursday, February 16, 2023
Align Biopharma, Veeva Systems, Novo Nordisk, Boehringer Ingelheim, MLR, NYSE, Patient, Boehringer, Marketing, Creativity, Mobile phone, Moderna

PLEASANTON, Calif., Feb. 16, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that biopharmas are leveraging Veeva Vault PromoMats for modular content to accelerate medical, legal, and regulatory (MLR) reviews and drive more impactful engagement across channels and regions. With eight of the top 10 biopharmas using Vault PromoMats for modular content, and over 20 emerging companies starting to set a foundation, the industry is making the push to digital to deliver personalized, compliant content faster, and at scale.

Key Points: 
  • "Our customers are at the forefront of digital marketing, paving the way with new modular strategies for more scalable and effective content," said Pooja Ojala, vice president of commercial content at Veeva.
  • Partnering with customers across more than 35 countries to establish a modular content foundation, Vault PromoMats is helping teams quickly reuse content and bridge the gap across channels and geographies.
  • Based on early indicators, a modular content approach is helping one customer reduce time to market by more than 50%.
  • "Reusing pre-approved content modules and tailoring relevant content is crucial to our modular content strategy as we customize more memorable, omnichannel experiences," said Jason Benagh, director of global marketing operations at Moderna.

Modular Content Powers Omnichannel Engagement at Speed and Scale

Retrieved on: 
Thursday, February 16, 2023
Align Biopharma, Veeva Systems, Novo Nordisk, Boehringer Ingelheim, MLR, NYSE, Patient, Boehringer, Marketing, Creativity, Mobile phone, Moderna

BARCELONA, Spain, Feb. 16, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that  biopharmas are leveraging Veeva Vault PromoMats for modular content to accelerate medical, legal, and regulatory (MLR) reviews and drive more impactful engagement across channels and regions. With eight of the top 10 biopharmas using Vault PromoMats for modular content, and over 20 emerging companies starting to set a foundation, the industry is making the push to digital to deliver personalized, compliant content faster, and at scale.

Key Points: 
  • "Our customers are at the forefront of digital marketing, paving the way with new modular strategies for more scalable and effective content," said Pooja Ojala, vice president of commercial content at Veeva.
  • Partnering with customers across more than 35 countries to establish a modular content foundation, Vault PromoMats is helping teams quickly reuse content and bridge the gap across channels and geographies.
  • Based on early indicators, a modular content approach is helping one customer reduce time to market by more than 50%.
  • "Reusing pre-approved content modules and tailoring relevant content is crucial to our modular content strategy as we customize more memorable, omnichannel experiences," said Jason Benagh, director of global marketing operations at Moderna.